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Abstract
Background: Concomitant thyroid and heart disease are frequently encountered in clinical 
practice. There are many studies evaluating thyroid function in acute and critical conditions. 
Information on thyroid dysfunction in ST-segment elevation myocardial infarction (STEMI) 
is limited; its correlation with short and long-term outcome is not fully known.
Methods: Four hundred and fifty seven patients diagnosed with STEMI in our emergency 
department were included in the study. Patients were divided into two groups: patients with 
normal thyroid function (euthyroid) and patients with thyroid dysfunction. STEMI was diag-
nosed with 12 derivation surface electrocardiogram. Thyroid hormone levels (TSH, free T3 
and free T4) were measured. Patients with other acute coronary syndromes and endocrine 
pathologies except diabetes mellitus were excluded. Two patient groups were compared in terms 
of in-hospital and long-term outcome.
Results: Out of 457, 72 (15%) patients with thyroid dysfunction were detected. The other pa-
tients were euthyroid and constituted the control group. In-hospital cardiogenic shock (15% vs. 
3% in the control group; p < 0.01) and death (7% vs. 1% in the control group; p < 0.01) were 
more frequently observed in the thyroid dysfunction group. In the subgroup analysis, it was 
observed that patients with sick euthyroid syndrome have the poorest outcome. Other markers 
for poor outcome were anemia and renal failure.
Conclusions: Thyroid dysfunction, particularly sick euthyroid syndrome, was found to be 
related to in-hospital and long term mortality in patients with STEMI undergoing primary 
percutaneous intervention. (Cardiol J 2014; 21, 3: 238–244)
Key words: thyroid dysfunction, sick euthyroid syndrome, ST segment elevation 
myocardial infarction
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Introduction
There is a close relationship between thyroid 
hormone levels and cardiovascular diseases [1]. 
Thyroid hormones critically regulate cardiac fun-
ction through several genes encoding important 
structural and functional proteins in the myocardium 
[2]. Both hypothyroidism and hyperthyroidism have 
been associated with increased risk of coronary 
artery disease in previous reports [3]. Thyroid hor-
mones also have been implicated in the mortality of 
other cardiac diseases like heart failure, arterial hy-
pertension, atherosclerosis and dyslipidemia [4–8].
There are many studies evaluating thyroid 
function in acute and critical conditions [9]. In-
formation on thyroid dysfunction in ST-segment 
elevation myocardial infarction (STEMI) is limited; 
its correlation with short and long-term outcome is 
not fully known. The aim of our study was to inve-
stigate the association between thyroid dysfunction 
and prognosis of STEMI patients who underwent 
primary coronary intervention.
Methods
Patient population
Our study was conducted between June 2010 
and June 2012 in Siyami Ersek Thoracic and Car-
diovascular Surgery Hospital, a tertiary reference 
center. We prospectively enrolled consecutive 
457 patients who received acute STEMI diagnosis in 
the emergency department of our hospital. Patients 
with other types of acute coronary syndrome, chro-
nic liver disease, kidney disease requiring dialysis, 
malignancy, active systemic infection, endocrine 
disease other than diabetes mellitus were excluded.
Informed consents of patients were obtained 
before the study. The study was authorized by the 
institutional ethics committee.
Data sources
Demographic data and clinical history concer-
ning age, sex, diabetes mellitus, hyperlipidemia, 
smoking, family history of coronary artery disease, 
earlier drug use were obtained from all patients. 
Electrocardiogram (ECG) was obtained from all 
patients after first medical contact for diagnosis. 
Blood pressures of all patients were measured at 
admission. Physical examination was also perfor-
med. All patients underwent coronary catheteriza-
tion for primary angioplasty after receiving aspirin 
(300 mg) and clopidogrel (300 mg loading dose). 
Angiographic data of the patients were collected 
from the cardiac catheterization laboratory records. 
Emergency cardiac catheterization was performed 
using percutaneous femoral approach using nonio-
nic iso-osmolar contrast media. A coronary artery 
stenosis more than 50% was considered clinically 
significant. Occlusion of the infarct related artery 
(IRA) was crossed by using a 0.014-inch guidewire. 
Primary angioplasty including balloon angioplasty 
and/or stent implantation was performed only for 
IRA based on the lesion anatomy.
Definitions
Patients who were admitted to emergency 
department of our hospital with typical ischemic 
symptoms (chest pain lasting for > 30 min) were 
diagnosed using 12 derivation surface ECG. When 
indicated, right (V3R–V4R) and posterior (V7–V9) 
derivations were also obtained. The ECG criteria 
for STEMI are ST-segment elevation of ≥ 2 mm 
in at least two contiguous leads or new onset of 
complete left bundle branch block.
Thyroid hormone levels of all patients; free 
T3, free T4 and TSH, were measured in the labo-
ratory of our hospital. The reference values of our 
laboratory are 0.34–5.0 µIU/mL for TSH; 0.59– 
–1.3 ng/dL for free T4; 2.3–4.0 pg/mL for free T3.
Patients with normal TSH and free T4 levels, 
and decreased free T3 levels were defined as sick 
euthyroid syndrome; increased TSH levels, normal 
free T3 and T4 levels as subclinical hypothyroi-
dism; increased TSH levels, decreased free T3 and 
T4 levels as overt hypothyroidism; decreased TSH 
levels, normal free T3 and T4 levels as subclinical 
hyperthyroidism; decreased TSH levels, increased 
free T3 and T4 levels as overt hyperthyroidism.
Subjects with thyroid dysfunction were com-
pared to subjects with normal thyroid function. 
As subjects with overt hypothyroidism (n = 2) 
and overt hyperthyroidism (n = 2) were very few, 
thyroid dysfunction patients were only subgrou-
ped as hypothyroidism, hyperthyroidism and sick 
euthyroid syndrome.
Collection of serum samples
Venous blood samples were collected from 
all patients within the first 12 h of admission for 
laboratory analysis.
Biochemical tests
Hemoglobin, hematocrit and platelet counts, 
blood glucose, creatinine, sodium, potassium, 
AST, ALT and CK-MB levels of all patients were 
measured at admission. Fasting lipid (triglycerides, 
LDL-cholesterol, HDL-cholesterol) and thyroid 
hormone levels were all measured in the laboratory 
of our hospital as well.
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Follow-up 
All patients were monitored for in-hospital 
major adverse cardiac event (MACE) throughout 
hospitalization. In-hospital MACE refers to ventri-
cular arrhythmias, recurrent infarct, target vessel 
revascularization (TVR), cardiogenic shock and 
death. Follow-up data were obtained from hospital 
records or by interviewing the patients (directly 
or by telephone), their families and personal phy-
sicians. Mean follow-up duration after discharge 
was 14.4 ± 5.4 months.
Statistical analysis
All data were presented as mean ± standard 
deviation for parametric variables and as per-
centages for categorical variables unless stated 
otherwise. Continuous variables were checked 
for the normal distribution assumption using 
the Kolmogorov-Smirnov statistics. Differences 
between patients and control subjects were evalu-
ated using the 2-sample t test and Mann-Whitney 
U test as appropriate. Categorical variables were 
tested by Pearson’s c2 test and Fisher’s Exact Test. 
For clinical outcomes, Kaplan-Meier estimates 
and curves were generated, and comparisons 
were made using log-rank test. Forward stepwi-
se multivariate logistic regression models were 
created to identify the independent predictors of 
in-hospital and long term adverse events. Variab-
les with a p value < 0.10 in univariate analysis 
were included in the multivariate model. The 
predictive value of thyroid function on clinical 
outcomes was examined using plasma levels of 
TSH, fT3 and freeT4 as continuous variables. In 
addition, we performed regression analysis using 
hypothyroidism, hyperthyroidism, sick euthyroid 
syndrome and control group as binary variables. All 
statistical studies were carried out using Statistical 
Package for Social Sciences software (SPSS 16.0 
for Windows, SPSS Inc., Chicago, Illinois) and 
a p < 0.05 was considered statistically significant.
Results
A total number of 457 patients with STEMI 
who were treated with primary percutaneous 
coronary intervention (PCI) were prospectively in-
cluded in our study. Seventy two patients (57 male; 
mean age 60.01 ± 13.87 years) had thyroid dysfun-
ction and 385 patients were with normal thyroid 
function (324 male; mean age 55.56 ± 12.29 years) 
which constituted the control group. Demographic 
and clinical properties of subjects with thyroid 
dysfunction and controls were depicted in Table 1. 
Patients with thyroid dysfunction were older 
(p < 0.01), had lower free T3, hemoglobin and higher 
creatinine levels. The other clinical, angiograp-
hic and laboratory parameters including plasma 
TSH and free T4 levels were similar between the 
two groups. Thyroid dysfunction group included 
17 subjects with hypothyroidism, 25 subjects with 
hyperthyroidism and 30 subjects with sick euthy-
roid syndrome. Seven of the patients with thyroid 
dysfunction had prior diagnosis of hypothyroidism 
and only 1 subject had prior diagnosis of hyper-
thyroidism.
In-hospital and long term clinical outcomes 
were listed in Table 2. Five (6.9%) patients with 
thyroid dysfunction and 5 (1.2%) patients with 
normal thyroid function died during hospitalization 
period. The incidence of MACE was significantly 
higher in patients with thyroid dysfunction (15.2% 
vs. 7.8%, p = 0.04) and was primarily driven by 
in-hospital mortality.
The mean follow-up period of participants was 
14.4 ± 5.4 months. During this period, 19 (29.2%) 
MACE occurred in patients with thyroid dysfunction 
and 61 (16.1%) MACE occurred in control group 
which was statistically significant (p = 0.01). The 
incidence of mortality and TVR was significantly 
higher in patients with thyroid dysfunction (p < 0.01, 
p = 0.04, respectively). In subgroup analysis, the 
incidence of in-hospital and long term mortality 
(n = 3/30 and 4/27 respectively) was highest in 
subjects with sick euthyroid syndrome.
Tables 3 and 4 list the independent predictors 
of in-hospital and long term MACE in study popu-
lation. Correlation of thyroid function with clinical 
outcomes was analyzed separately as continuous 
variables and subgroups of thyroid function namely 
control, hypothyroidism, hyperthyroidism and 
sick euthyroid syndrome. In univariate analysis, 
age, left ventricular ejection fraction, admission 
glucose levels, peak CK-MB levels and presence 
of sick euthyroid syndrome were associated with 
in-hospital MACE. Plasma levels of free T3 were 
weakly associated with in-hospital MACE only in 
univariate analysis but not in multivariate analysis. 
In multivariate analysis, increased age (HR 1.03, 
95% CI 1.01–1.06, p = 0.02) and presence of sick 
euthyroid syndrome (HR 3.30, 95% CI 1.22–8.94, 
p = 0.02) were the only independent predictors of 
in-hospital MACE.
Univariate logistic regression analysis reve-
aled age, female gender, admission hemoglobin, 
creatinine, free T3 levels, peak CK-MB levels and 
presence of sick euthyroid syndrome as predictors 
of long term MACE with p values lower than 0.10. 
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However, in multivariate analysis increased age 
and presence of sick euthyroid syndrome (HR 
2.83, 95% CI 1.16–6.88, p = 0.02) were the only 
independent predictors. The Kaplan-Meier esti-
mate of long term survival free from MACE was 
significantly worse in patients with sick euthyroid 
syndrome (Fig. 1).
Discussion
Thyroid hormones have important effects on 
the cardiovascular system through direct and indi-
rect mechanisms [1]. Although STEMI and thyroid 
disorders are not directly related, the relationship 
between atherosclerosis and hypothyroidism as 
Table 2. Comparison of in-hospital and long term major adverse cardiovascular events (MACE) in  
patients with thyroid dysfunction and control subjects.
Thyroid dysfunction (n = 72) Control (n = 385) P
In-hospital MACE: 11/72 30/385 0.04
Recurrent myocardial infarction 5/72 26/385 0.90
Target vessel revascularization 6/72 24/385 0.68
Mortality 5/72 5/385 < 0.01
Long term MACE: 19/65 61/380 0.01
Recurrent myocardial infarction 11/65 47/380 0.34
Target vessel revascularization 12/65 37/380 0.04
Mortality 6/65 8/380 < 0.01
Table 1. Baseline characteristics of the study population.
Thyroid dysfunction (n = 72) Control (n = 385) P
Age 60.01 ± 13.87 55.56 ± 12.29 < 0.01
Male gender 57 (79.1%) 324 (84.1%) 0.30
Hypertension 37 (51.3%) 166 (43.1%) 0.19
Diabetes mellitus 15 (20.8%) 90 (23.3%) 0.63
Hyperlipidemia 17 (23.6%) 76 (19.7%) 0.45
Smoking 48 (66.6%) 281 (72.9%) 0.27
Family history for CAD 19 (26.4%) 122 (31.6%) 0.57
Thyroid function:
Hypothyroidism 17 (23.6%) –
Hyperthyroidism 25 (34.7%) –
Sick euthyroid syndrome 30 (41.6%) –
Systolic BP [mm Hg] 122.80 ± 34.93 124.43 ± 23.38 0.70
Diastolic BP [mm Hg] 73.73 ± 18.84 77.20 ± 52.98 0.68
Anterior MI 27 167 0.35
Pain-to-balloon time 5.29 6.20 0.24
Multivessel disease 43 (59.7%) 211 (54.8%) 0.38
Laboratory parameters:
Hemoglobin 13.05 ± 1.61 14.04 ± 1.73 < 0.01
Glucose 162.02 ± 69.15 160.52 ± 78.80 0.88
Creatinine 1.06 ± 045 0.91 ± 0.34 < 0.01
Trygliceride 142.19 ± 74.49 162.76 ± 108.26 0.12
Total cholesterol 181.55 ± 53.96 189.35 ± 42.88 0.22
LDL cholesterol 116.84 ± 40.22 119.89 ± 34.58 0.50
HDL cholesterol 38.74 ± 11.44 37.29 ± 10.49 0.30
Peak CK-MB 165.54 ± 143.97 165.99 ± 139.06 0.98
TSH 2.15 ± 3.01 1.64 ± 0.95 0.15
fT3 2.46 ± 0.80 2.90 ± 0.42 < 0.01
fT4 1.20 ± 0.42 1.12 ± 0.28 0.14
CAD — coronary artery disease; BP — blood pressure; MI — myocardial infarction
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Table 3. Effects of multiple variables on the in-hospital major adverse cardiac event in univariate and 
multivariate logistic regression analyses.
Variables Unadjusted odds  
ratio (95% CI)
P Adjusted odds ratio* 
(95% CI)
P
Age 1.04 (1.01–1.065) < 0.01 1.03 (1.01–1.06) 0.02
Male gender 0.68 (0.31–1.48) 0.32
Hypertension 1.52 (0.79–2.89) 0.21
Diabetes mellitus 1.84 (0.82–3.65) 0.11
Smoking 1.43 (0.66–3.09) 0.36
Anterior myocardial infarction 0.85 (0.44–1.63) 0.63
Pain-to-balloon time 0.99 (0.98–1.01) 0.66
No-reflow 0.62 (0.19–2.07) 0.44
Multivessel disease 1.26 (0.65–2.43) 0.49
Left ventricular ejection fraction 0.96 (0.93–1.01) 0.05 0.98 (0.94–1.02) 0.40
Hemoglobin 0.89 (0.75–1.07) 0.22
Glucose 1.004 (1.001–1.007) 0.04 1.004 (1.0–1.008) 0.08
Creatinine 1.60 (0.76–3.38) 0.21
Peak CK-MB 1.002 (1.00–1.004) 0.02 1.001 (0.99–1.004) 0.23
TSH 0.87 (0.65–1.14) 0.31
fT3** 0.60 (0.33–1.10) 0.09 0.75 (0.37–1.51) 0.42
fT4 1.91 (0.81–4.46) 0.14
Hypothyroidism** 0.78 (0.11–6.16) 0.81 1.07 (0.13–8.84) 0.94
Hyperthyroidism** 1.61 (0.45–5.68) 0.46 1.61 (0.43–6.03) 0.47
Sick euthyroid syndrome** 3.59 (1.42–9.05) < 0.01 3.30 (1.22–8.94) 0.02
*Adjusted for age, left ventricular ejection fraction, plasma glucose and peak CK-MB levels; **fT3 and subgroups of thyroid dysfunction were 
analyzed separately
Table 4. Effects of multiple variables on long term major adverse cardiac event in univariate and  
multivariate logistic regression analyses.
Variables Unadjusted odds  
ratio (95% CI)
P Adjusted odds ratio*  
(95% CI)
P
Age 1.03 (1.01–1.05) < 0.01 1.03 (1.01–1.05) 0.02
Male gender 0.49 (0.28–0.89) 0.02 0.64 (0.31–1.31) 0.22
Hypertension 1.24 (0.77–2.02) 0.38
Diabetes mellitus 1.13 (0.64–1.98) 0.66
Smoking 0.81 (0.49–1.39) 0.46
Anterior myocardial infarction 1.03 (0.66–1.67) 0.90
Pain-to-balloon time 1.00 (0.99–1.01) 0.73
No-reflow 0.87 (0.39–1.94) 0.74
Multivessel disease 0.72 (0.44–1.18) 0.19
Left ventricular ejection fraction 0.98 (0.96–1.01) 0.31
Hemoglobin 0.86 (0.75–0.98) 0.03 1.02 (0.86–1.21) 0.84
Glucose 1.00 (0.99–1.003) 0.95
Creatinine 1.77 (0.98–3.17) 0.06 1.37 (0.73–2.59) 0.32
Peak CK-MB 1.002 (1.00–1.003) 0.04 1.002 (1.0–1.003) 0.07
TSH 0.90 (0.75–1.08) 0.28
fT3** 0.63 (0.39–1.02) 0.06 0.91 (0.53–1.56) 0.79
fT4 1.26 (0.61–2.64) 0.53
Hypothyroidism** 0.77 (0.18–3.64) 0.77 0.78 (0.16–3.66) 0.75
Hyperthyroidism** 1.73 (0.66–4.55) 0.26 1.79 (0.66–4.85) 0.25
Sick euthyroid syndrome** 3.58 (1.58–8.09) < 0.01 2.83 (1.16–6.88) 0.02
*Adjusted for age, gender, left ventricular ejection fraction, plasma hemoglobin, creatinine and peak CK-MB levels; **fT3 and subgroups of 
thyroid dysfunction were analyzed separately
www.cardiologyjournal.org 243
Kazım Serhan Özcan et al., Thyroid dysfunction and myocardial infarction
Figure 1. Kaplan-Meier estimates of survival free of ma-
jor adverse cardiac event (death, myocardial infarction, 
and target lesion revascularization) among thyroid fun-
ction subgroups.
well as cardiac arrhythmias and hyperthyroidism 
are well known [1, 3, 7].
The main finding of our study was that both 
in-hospital and long term mortality were higher 
in the study group. Subgroup analysis revealed 
that these results were mainly driven by the high 
rates of mortality in patients with sick euthyroid 
syndrome.
Sick euthyroid syndrome is frequently ob-
served in chronic heart failure, acute myocardial 
infarction (AMI) and following cardiac surgery. It is 
related to increased mortality in both heart failure 
and AMI [10–14].
Similar results were found in previous stu-
dies. In the study conducted by Pimentel et al. 
[15] which included 70 patients with both STEMI 
and non-STEMI, in-hospital mortality of the sick 
euthyroid group was higher. Compared to our study, 
sample size was small and results cover only short 
term mortality.
Thyroid hormone, apart from its “classical” 
actions on cardiac contractility and heart rhythm, 
appears to regulate various intracellular signa-
ling pathways related to response to stress and 
cardiac remodeling. It affects cardiac remodeling 
by limiting reperfusion injury, and, at later states, 
by inducing distinct changes in cardiac chamber 
geometry in a time-dependent manner [16, 17].
Friberg et al. [18] conducted a study measuring 
reverse T3 levels of 331 patients with myocardial 
infarction. Increased reverse T3 levels were found 
to be related to increased 1-year mortality. The 
increase in reverse T3 signifies decreased free T3, 
which is the underlying cause of sick euthyroid syn-
drome. This parameter, which was not measured 
in our study, is a direct indicator of sick euthyroid 
syndrome. However, in terms of long term results, 
the study correlates with our findings.
The important role of thyroid hormone in the 
regulation of cardiac vasculature is further confir-
med by the impaired coronary artery contraction, 
the reduced density of small arterioles, and the 
altered echocardiographic parameters reported in 
low thyroid function [19].
Consistent with our results, in a study conduc-
ted by Lazzeri et al. [20] on 641 STEMI patients, 
the in-hospital mortality of the sick euthyroid group 
was higher. The patients in this study were trea-
ted with PCI. The failure of intervention was also 
higher in patients with sick euthyroid syndrome.
Molinaro et al. [21] followed 1026 patients 
with acute cardiac diseases for 30 months after 
diagnosis. Cardiac mortality was found to be higher 
in the group with subclinical hypothyroidism and 
sick euthyroid syndrome. Our findings support the 
results of prior studies and indicate the prognostic 
implications of thyroid hormone levels on long-
-term adverse cardiac events.
In conclusion, a low free T3 level, a common 
phenomenon in patients with AMI, is a strong pre-
dictor of short-term and long-term poor prognoses 
in STEMI patients treated with primary PCI. The 
techniques used in detecting hormone levels are 
highly sensitive and available almost everywhere in 
modern era. Therefore, they can easily be used for 
predicting the in-hospital and long term prognosis 
in a high-mortality patient group.
Limitations of the study
This is a medium sized study covering both 
short and long term results. Reverse T3 levels 
were not measured along with other parameters. 
The results cannot be generalized to other patient 
groups because it only comprises patients diagno-
sed with STEMI.
Conclusions
STEMI is a frequently encountered diagnosis 
and still an important cause of mortality. Various 
scoring systems are proposed to predict short and 
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long term prognoses. These scoring systems have 
limitations and do not include every parameter. In 
our study, thyroid dysfunction and especially sick 
euthyroid syndrome were found to be related to 
adverse outcomes. These results warrant further 
study.
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